GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ACHL
Achilles is a biotech company developing personalized cell therapy for cancer. Its stock price represents a venture capital bet on the success of its innovative approach. The chart reflects high volatility and dependence on clinical trial news.
Share prices of companies in the market segment - Oncology cell gene therapy
Achilles Therapeutics is a biopharmaceutical company developing personalized T-cell-based cell therapies for the treatment of solid tumors. We've categorized it under "Oncology: Cell Therapies." The chart below shows how the market is valuing this complex biotech sector.
Broad Market Index - GURU.Markets
Achilles Therapeutics is a British biopharmaceutical company developing personalized cell therapies for the treatment of solid tumors. As a component of the GURU.Markets index, it is at the forefront of oncology. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
ACHL - Daily change in the company's share price ACHL
Achilles Therapeutics plc's daily price change reflects the extreme volatility inherent in cell therapy companies. This metric measures sensitivity to clinical trial data, serving as a risk assessment element.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Achilles Therapeutics develops personalized T-cell therapy for solid tumors. The cell therapy sector is one of the most advanced and volatile in biotech. The chart below reflects the average fluctuations in this industry, serving as a benchmark for valuing ACHL stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Achilles Therapeutics is a biotech company working on cell therapy. Its shares are a bet on a scientific breakthrough. Their extreme volatility, driven by research data, is part of the dynamics of the innovation sector, which impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ACHL
Achilles Therapeutics' year-to-date performance is a story of personalized cell therapy development. Its 12-month market cap is entirely dependent on early clinical trial data. The success of its approach, which uses T cells targeting unique tumor mutations, could be a breakthrough in the treatment of solid cancers.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
As an early-stage biotech, Achilles is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cell therapy. Its stock price will reflect investors' speculative belief in its potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Achilles Therapeutics, a developer of personalized cell therapy for solid tumors, is at the forefront of oncology. Its year-over-year market capitalization is a barometer of investor hopes for its unique technology. Its share price moves in sync with scientific data, not economic news.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ACHL
Achilles is an oncology company developing personalized T-cell therapy. Being in the clinical stage, its monthly evaluation is entirely dependent on news. Trial results confirming the efficacy of its unique technology are the primary driver.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Achilles Therapeutics is developing personalized T-cell therapy for solid tumors, targeting cancer mutations unique to each patient. The chart below reflects the current state of the art in the cell and gene therapy sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Achilles Therapeutics is a biotech company developing cell therapies for the treatment of solid tumors. Its shares represent a venture capital investment in breakthrough medical technologies. Its performance is completely unrelated to the market and is determined by scientific successes and failures.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ACHL
Shares of Achilles Therapeutics, a company developing personalized cancer immunotherapy, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials of their complex and innovative technology. The chart below illustrates how short-term scientific events shape the value of the company at the forefront of oncology.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Achilles Therapeutics is developing personalized cell therapy for cancer treatment. This is one of the most complex and promising approaches in oncology. The chart shows how any news about research successes or failures triggers sharp fluctuations in the stock price, unrelated to the market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Achilles Therapeutics is a biotech company focused on cell therapy. This chart shows how out of sync its weekly performance is with the broader market. Its stock price is driven by news about clinical trials and scientific progress, not the overall economic situation.
Market capitalization of the company, segment and market as a whole
ACHL - Market capitalization of the company ACHL
Achilles Therapeutics' market capitalization is a bet on its cutting-edge approach to developing personalized cell therapy for cancer, targeting tumor neoantigens unique to each patient. The company's valuation reflects the enormous scientific potential and equally enormous risks of this complex approach.
ACHL - Share of the company's market capitalization ACHL within the market segment - Oncology cell gene therapy
Achilles Therapeutics's stake in oncology stems from its focus on cutting-edge cell therapies targeting tumor antigens unique to each patient. Its market share reflects the enormous, albeit risky, potential for creating truly personalized cancer treatments.
Market capitalization of the market segment - Oncology cell gene therapy
The chart below is a barometer of the biotech sector developing personalized cancer vaccines. Achilles Therapeutics is a pioneer in this field. The dynamics in the chart reflect the enormous hopes and scientific risks associated with this revolutionary approach.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market value of cutting-edge cancer immunotherapy. Achilles Therapeutics' market cap is a bet on its personalized T-cell vaccine technology. The line shows how fundamental science targeting unique tumor mutations is shaping its enormous potential share of the future of oncology.
Book value capitalization of the company, segment and market as a whole
ACHL - Book value capitalization of the company ACHL
Achilles Therapeutics' book value represents its scientific and production capital. The chart below reflects the valuation of its patents for its platform for creating personalized T-cell cancer therapy. The pipeline's growth reflects investments in the development of this complex and individualized approach to cancer treatment.
ACHL - Share of the company's book capitalization ACHL within the market segment - Oncology cell gene therapy
Achilles Therapeutics' core asset is its manufacturing capabilities for developing personalized cell therapies for cancer. The chart shows the company's share of this advanced and capital-intensive manufacturing infrastructure, which is key to its innovative approach.
Market segment balance sheet capitalization - Oncology cell gene therapy
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Achilles Therapeutics, a cell therapy developer, has a more streamlined model. Its value lies in its unique scientific platform, not in the scale of its production.
Book value of all companies included in the broad market index - GURU.Markets
Achilles Therapeutics is developing personalized cell therapy for cancer treatment. The company's assets include unique production laboratories where they "train" patients' T cells to attack their own tumors. The chart below illustrates the financial weight behind this highly complex "living" therapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ACHL
Achilles Therapeutics is an oncology company developing personalized cell therapy. Its market value is derived from its cutting-edge, yet highly complex and expensive, scientific platform. It's a bet on the future of personalized medicine.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Achilles Therapeutics plc is a biotechnology company developing personalized cell therapy for cancer. Its value lies in this cutting-edge technology. This chart shows how its market valuation, based on expectations for a breakthrough in oncology, is a multiple of its book value.
Market to book capitalization ratio for the market as a whole
Achilles Therapeutics develops cell therapy for solid tumors. Its market valuation, as shown in this chart, is based solely on the potential of its innovative technology. Investors are betting on a breakthrough in personalized oncology.
Debts of the company, segment and market as a whole
ACHL - Company debts ACHL
Achilles Therapeutics, a company developing personalized cell therapies for cancer, uses raised capital to fund its complex and expensive research. This chart shows how the company spends hundreds of millions of dollars on R&D and clinical trials, working at the forefront of oncology.
Market segment debts - Oncology cell gene therapy
Achilles Therapeutics is a biotech company developing personalized cell therapies for cancer treatment. This cutting-edge approach is extremely complex and expensive. This chart shows how its financial structure, with virtually no debt, reflects its early stage development, which is financed exclusively by equity.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ACHL
Acasti Pharma focuses on developing drugs to treat rare cardiovascular diseases. This chart shows the company's financial position during its lengthy clinical development journey. Debt management is critical to survival until potential approval and product launch.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Achilles Therapeutics is a biotech company developing personalized cell therapies for solid tumors. This chart compares its debt load to the overall market capitalization of the oncology sector. It shows how the company is funding its cutting-edge and capital-intensive research in T-cell therapy.
Debt to book value of all companies in the market
Achilles Therapeutics develops personalized cell therapies for cancer treatment, targeting tumor antigens unique to each patient. This is at the forefront of oncology. This graph of total debt in the market shows the overall risk appetite, which is critical for a company raising vast amounts of capital for its science-intensive and expensive developments.
P/E of the company, segment and market as a whole
P/E - ACHL
For Achilles Therapeutics, a company developing cell therapy for cancer, the P/E ratio is not applicable. The company has no profit, and its valuation on this chart is arbitrary. It is a speculative bet that its unique approach to creating personalized medicines will prove successful.
P/E of the market segment - Oncology cell gene therapy
Achilles Therapeutics is a biotech company developing personalized T-cell therapy for cancer. Their approach is based on the use of immune cells that target neoantigens unique to each tumor. This chart shows the average valuation for the oncology sector, reflecting the premium investors are willing to pay for advanced and sophisticated personalized immunotherapy approaches.
P/E of the market as a whole
Achilles Therapeutics is a biopharmaceutical company developing personalized T-cell therapy for solid tumors. The company's approach is based on targeting tumor antigens unique to each patient. This risk appetite chart helps understand how investors evaluate cutting-edge immuno-oncology technologies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ACHL
Achilles Therapeutics is developing personalized T-cell therapy for solid tumors, targeting neoantigens unique to each patient. This chart reflects investors' confidence in the breakthrough potential of this technology. Future revenue depends on the success of clinical trials.
%20P%2FE%20ACHL&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ACHL&v=1772596264912 "Chart of the company's future (projected) P/E ACHL")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Achilles Therapeutics is developing personalized cell therapy for solid tumors, targeting neoantigens unique to each patient. This chart reflects investor confidence in its cutting-edge yet complex scientific approach. It compares expectations for Achilles with other cell therapy companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772596264993 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Achilles Therapeutics is developing personalized T-cell therapy for solid tumors. This is the cutting edge of oncology, requiring massive investment. This chart, reflecting market optimism, demonstrates investors' appetite for risk, which is vital for funding such revolutionary, yet long-term and capital-intensive, medical projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772596265105 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ACHL
Achilles Therapeutics is a biopharmaceutical company developing personalized cell therapies for solid tumors. Its financial profile is typical for biotech: high R&D and clinical trial costs. This chart shows the investment required to develop breakthrough cancer treatments.
Profit of companies in the market segment - Oncology cell gene therapy
Achilles Therapeutics develops personalized T-cell therapy for solid tumors. This graph, showing overall sector profitability, reflects the company's leading edge in the fight against cancer. Achilles' unique approach, targeting cancer neoantigens, could revolutionize oncology and generate significant profits for the entire industry if successful.
Overall market profit
Achilles Therapeutics is developing personalized cell therapy for cancer treatment. The technology utilizes a patient's immune cells to target unique mutations in their tumor. This is at the forefront of oncology, and the company's value is determined by its scientific potential.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ACHL
Achilles Therapeutics develops personalized cell therapy for the treatment of solid tumors. Future revenue projections are speculative and depend on the success of clinical trials. Analysts are evaluating the potential of its innovative approach to immuno-oncology.
%20profit%20of%20the%20company%20ACHL&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ACHL&v=1772596265351 "Graph of future (projected) profit of the company ACHL")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Achilles Therapeutics develops personalized cell therapy for solid tumors, targeting neoantigens unique to each patient. This chart shows revenue projections for the cell and gene therapy oncotherapy segment. It allows one to assess how the company's cutting-edge technology compares to financial expectations for this revolutionary field of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772596265445 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Achilles Therapeutics is developing personalized cell therapy for the treatment of solid tumors. This is a cutting-edge, but very expensive technology. This graph, reflecting the investment climate, is critically important. During periods of optimism, investors are willing to fund breakthrough but capital-intensive oncology projects, which Achilles needs to continue its development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772596265465 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ACHL
Achilles Therapeutics is a biotech company developing personalized cell therapies for the treatment of solid tumors. This metric, which correlates market capitalization with minimum revenue, reflects pure potential and demonstrates how highly investors value its innovative approach based on the use of patient-derived immune cells.
P/S market segment - Oncology cell gene therapy
Achilles Therapeutics is developing personalized T-cell therapy for solid tumors. The company's approach is based on targeting cancer antigens unique to each patient. This chart reflects the market's willingness to pay for cell therapy revenue, demonstrating confidence in the breakthrough potential of personalized oncology.
P/S of the market as a whole
Achilles Therapeutics is a biopharmaceutical company developing personalized T-cell therapy for solid tumors, targeting neoantigens unique to each patient. This chart, showing the average valuation, highlights that investors value the company based on its breakthrough scientific approach.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ACHL
Achilles Therapeutics is developing personalized cell therapy for solid tumors. This chart shows the market's estimate of its potential future revenue. It reflects investors' belief in the breakthrough nature of its technology and the enormous commercial potential should it succeed in clinical trials.
%20P%2FS%20ACHL&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ACHL&v=1772596265758 "The graph of the company's future (projected) P/S ACHL")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Achilles Therapeutics is a biotechnology company developing personalized T-cell therapy for solid tumors. This chart shows the median estimated future revenue in the cell/gene therapy oncotherapy sector. It helps understand how investors view Achilles's cutting-edge yet complex scientific approach and its long-term commercial prospects.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772596265909 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Achilles Therapeutics (ACHL) is developing innovative cell-based cancer therapies that target neoantigens unique to each patient. Their potential lies at the cutting edge of science. This timeline is unrelated to their mission to create personalized drugs that could revolutionize oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772596265939 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ACHL
Achilles Therapeutics is at the forefront of cancer cell therapy. Being in the clinical stage, the company has no sales revenue. Its financial history is based on investments in the development of personalized T-cell therapies. The graph will reflect future revenue from partnerships or commercialization of its breakthrough technology.
Sales of companies in the market segment - Oncology cell gene therapy
Achilles Therapeutics is an oncology company developing personalized T-cell therapy. Its unique approach targets tumor clonal neoantigens. While in the clinical stage, it has no revenue yet, but its technology represents the cutting edge of immuno-oncology.
Overall market sales
Achilles Therapeutics plc develops personalized cell therapy for the treatment of solid tumors. As a clinical-stage company, its value is determined by scientific progress. The overall economic situation, shown in this chart, influences the overall investment climate in biotech and the ability to attract significant capital for complex and expensive research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ACHL
Achilles Therapeutics is developing personalized T-cell therapy for solid tumors. Future revenue depends on the success of its innovative approach. This chart represents the company's long-term potential in cellular oncology.
%20sales%20of%20the%20company%20ACHL&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ACHL&v=1772596266101 "Schedule of future (projected) sales of the company ACHL")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Achilles Therapeutics is developing personalized T-cell therapy for solid tumors, targeting neoantigens unique to each patient. This graph shows the outlook for the cell and gene therapy sector. It reflects the cutting edge of cancer treatment and the high potential of personalized approaches.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772596266140 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Investment activity in the pharmaceutical industry, closely linked to the forecasts in this chart, determines the prospects for Achilles Therapeutics. The company is developing cell therapies for cancer treatment. Funding for such cutting-edge and expensive research depends on the overall state of financial markets.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772596266221 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ACHL
Achilles Therapeutics is developing personalized T-cell therapy for solid tumors. This schedule reflects its massive investment in cutting-edge oncology. Profitability is a long-term goal, dependent on the success of this complex technology, which requires the creation of a unique drug for each patient.
Market segment marginality - Oncology cell gene therapy
Achilles Therapeutics is a biopharmaceutical company developing personalized T-cell therapy for the treatment of solid tumors. Profitability depends on the success of its complex and innovative technology. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the potential and risks associated with Achilles's cutting-edge approach.
Market marginality as a whole
Achilles Therapeutics is developing personalized cell therapy for cancer treatment. This cutting-edge technology requires significant investment. The company's future depends on clinical results and funding. This chart shows the overall market risk appetite, which determines whether investors are willing to invest in revolutionary, but very expensive, medical developments.
Employees in the company, segment and market as a whole
Number of employees in the company ACHL
Achilles Therapeutics is a biopharmaceutical company developing personalized cell therapies for the treatment of solid tumors. This graph shows the size of its team of scientists and clinicians. The growth in the graph reflects progress in developing their complex technology and expanding clinical trials, which requires significant scientific resources.
Share of the company's employees ACHL within the market segment - Oncology cell gene therapy
Achilles Therapeutics is developing personalized cell therapy for solid tumors, targeting neoantigens unique to each patient. This chart shows the percentage of all scientists in this cutting-edge field the company employs. This reflects its sophisticated scientific approach and potential for cancer treatment.
Number of employees in the market segment - Oncology cell gene therapy
Achilles Therapeutics is a biopharmaceutical company developing personalized T-cell therapy for solid tumors. This chart, reflecting activity in the cell and gene therapy sector, is important. The growing number of scientists in this cutting-edge field reflects the race to develop breakthrough cancer treatments that target unique tumor antigens.
Number of employees in the market as a whole
Achilles Therapeutics develops personalized cell therapy for cancer treatment. This is one of the most advanced areas of medicine. This total employment chart reflects the economic base that can support such expensive research. Only with stable growth is the long-term investment necessary to create the drugs of the future possible.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ACHL (ACHL)
Achilles Therapeutics (ACHL) is an immuno-oncology company developing cell therapy (T-cells) for cancer treatment. As with any biotech R&D company, this metric reflects not current performance but market confidence in their science. A small team of scientists is working with intellectual property that, if successful, could be worth billions.
%20of%20the%20company%20ACHL%20(ACHL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ACHL-ACHL&v=1772596266529 "Chart of market capitalization per employee (in thousands of dollars) of the company ACHL (ACHL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Achilles Therapeutics develops cell therapy for cancer based on the analysis of tumor mutations. This is cutting-edge and complex science. This metric demonstrates that the company's market capitalization is determined by its unique technology and intellectual property, rather than by the size of its workforce, which is typical of biotech pioneers.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772596266580 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Achilles Therapeutics develops personalized cell therapy for cancer treatment. This is a cutting-edge field in medicine. This chart shows the extremely high valuation per employee, as the market cap reflects the potential of this revolutionary technology, developed by a small team of scientists, to change the paradigm of cancer treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772596266617 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ACHL (ACHL)
Achilles Therapeutics is a biotech company developing cutting-edge cell therapy (based on T cells) for cancer treatment. This R&D is highly personalized and expensive. This chart shows not profit, but the "cost of innovation": how much the company invests (negative profit) per scientist to create this "living medicine."
%20Chart%20ACHL%20(ACHL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ACHL-ACHL&v=1772596266670 "Company Profit Per Employee (in thousands of dollars) Chart ACHL (ACHL)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Achilles Therapeutics develops personalized cell therapy for the treatment of solid tumors. For a research-stage biotech company, this graph reflects the efficiency of managing complex and expensive R&D processes. Positive performance in this indicator will be directly linked to success in clinical trials and future partnerships.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772596266688 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Achilles Therapeutics (ACHL) is a biotech company developing personalized T-cell therapy (based on neoantigens) for the treatment of cancer. This is cutting-edge cell therapy (R&D). There is no profit. This metric is negative and reflects the high "cost" of a single scientist working to create a unique drug for each patient.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772596266750 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ACHL (ACHL)
Achilles Therapeutics is developing personalized cell therapy for cancer. There is no revenue at the clinical development stage. This chart shows the dormant potential: if successful, their highly sophisticated technology could generate enormous revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ACHL-ACHL&v=1772596266825 "Sales chart per company employee ACHL (ACHL)")
Sales per employee in the market segment - Oncology cell gene therapy
Achilles Therapeutics is a biotech company developing personalized T-cell cancer therapy. This is incredibly complex science. This chart reflects their R&D status. The company has no commercial revenue. The productivity of their team of elite scientists is measured not by sales, but by progress in creating "living drugs."
Sales per employee for the market as a whole
MRC Global (MRC) is a leading distributor of pipes, valves, and fittings (PVF) for the energy industry (oil and gas, petrochemicals). These products are a critical link in the MRO (maintenance, repair, and operations) supply chain. This chart reflects efficiency in industrial distribution. MRC's success depends on inventory and logistics management. The growth of this metric demonstrates their ability to handle large orders with optimized staffing.
Short shares by company, segment and market as a whole
Shares shorted by company ACHL (ACHL)
Achilles Therapeutics (ACHL) is developing a complex cell therapy (CAR-T) for cancer treatment. This chart shows the number of short positions. The short positions reflect a bet that this extremely expensive and complex technology will not prove effective.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ACHL-ACHL&v=1772596266970 "Short Shares Chart for the Company ACHL (ACHL)")
Shares shorted by market segment - Oncology cell gene therapy
Achilles Therapeutics (ACHL) is developing personalized cell therapy (based on T cells) for cancer treatment. The chart below shows the overall short position in the gene therapy sector. It illustrates how concerned investors are about the complexity of production and the high cost of such treatments.
Shares shorted by the overall market
Achilles (ACHL) is a biotech company focused on cell therapy. It's one of the most cutting-edge and speculative technologies. When this market fear indicator rises, investors aren't willing to wait 10 years. They're selling off profit-less "research projects" en masse, like ACHL, to cash out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ACHL (ACHL)
This chart for Achilles is an indicator of faith in "personalized" oncology. The company is developing complex cell therapies (TILs) targeting the unique mutations of a patient's tumor. "Overheating" (above 70) occurs due to positive early data. High costs, manufacturing complexity, and the risk of failure lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ACHL-ACHL&v=1772596267057 "RSI 14 indicator chart for the company's stock ACHL (ACHL)")
RSI 14 Market Segment - Oncology cell gene therapy
Achilles is a "biotech" and a "sniper" in oncology (TILs 2.0). Their *platform* (PELEUS) *finds* unique "targets" (*neoantigens*) on *each* tumor for *personalized* T-cell therapy. The "Oncology cell gene therapy" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of *the entire* segment. It helps us understand: is ACHL's growth due to their R&D, or is *the entire* biotech "overheated"?
RSI 14 for the overall market
Achilles Therapeutics (ACHL) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ACHL (ACHL)
Achilles Therapeutics (ACHL) is an immuno-oncology company developing personalized cell therapy (TIL) based on "clonal neoantigens." This chart shows the average target price, reflecting analysts' faith in this complex yet cutting-edge cancer treatment technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ACHL-ACHL&v=1772596267157 "A chart showing analyst consensus forecasts for the expected stock price. ACHL (ACHL)")
The difference between the consensus estimate and the actual stock price ACHL (ACHL)
Achilles Therapeutics (ACHL) is a biotech company developing personalized T-cell therapy (TILs) for the treatment of solid tumors. This chart shows the upside and downside potential analysts see for the stock. It measures the gap between the price and forecast, reflecting their belief in this complex, "custom" oncology company.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ACHL-ACHL&v=1772596267185 "A chart showing the difference between the consensus forecast and the actual stock price. ACHL (ACHL)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Achilles Therapeutics is a biotech company developing "personalized" cell therapies (TILs) targeting unique "neoantigens" in a patient's tumor. This chart shows general expectations for the oncology sector. It reflects whether experts believe a breakthrough in "ultra-personalized" cancer treatment is possible.
Analysts' consensus forecast for the overall market share price
Achilles Therapeutics (ACHL) is a biopharmaceutical company at the forefront of personalized cancer treatment. They use AI to identify "neoantigens" and create T-cell therapies for each patient. This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough, but extremely expensive, R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ACHL
Achilles Therapeutics is a biotech R&D company working in the hottest area of cell therapy—TILs (tumor-infiltrating lymphocytes). Their signature approach is personalized: they target clonal neoantigens (unique tumor markers). This graph is a clear indicator of their faith in their deep science, reflecting their (highly risky) R&D progress.
AKIMA Market Segment Index - Oncology cell gene therapy
Achilles Therapeutics is a cell-based gene therapy company specializing in oncology. Their unique approach involves engineering T cells that attack errors (neoantigens) unique to each patient's tumor. This graph compares their composite index to the sector, showing how their personalized therapy compares to others.
The AKIM Index for the overall market
Achilles Therapeutics is an immuno-oncology company developing personalized T-cell therapies targeting clonal neoantigens. This chart, reflecting the market average, is an indicator of risk appetite. It illustrates the macro backdrop critical to funding this precision science platform.
